CIK 0001824893 · Non-accelerated filer<br>Smaller reporting company
Surrozen, Inc./DE
Sign in to watch- Ticker
- SRZN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 301374889
- Phone
- 650-475-2820
- Business address
- 171 OYSTER POINT BLVD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Consonance-HFW Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 54 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-20 | COLUMN GROUP III GP, LP 10% owner | Option exercise | +485,830 | $11.60 | $5.6M | 1,386,122 |
| 2026-10-20 | COLUMN GROUP III GP, LP 10% owner | Option exercise | +548,653 | $11.60 | $6.4M | 1,565,311 |
| 2026-10-20 | COLUMN GROUP III GP, LP 10% owner | Option exercise | +517,241 | $11.60 | $6.0M | 862,068 |
| 2026-10-20 | COLUMN GROUP III GP, LP 10% owner | Option exercise · Second Tranche Units (Right to Buy) | −728,745 | 0 | ||
| 2026-10-20 | COLUMN GROUP III GP, LP 10% owner | Option exercise · Second Tranche Units (Right to Buy) | −822,980 | 0 | ||
| 2026-10-20 | COLUMN GROUP III GP, LP 10% owner | Option exercise · Second Tranche Units (Right to Buy) | −775,861 | 0 | ||
| 2026-10-20 | COLUMN GROUP III GP, LP 10% owner | Option exercise · Series E Common Warrants | +242,915 | 404,858 | ||
| 2026-10-20 | COLUMN GROUP III GP, LP 10% owner | Option exercise · Series E Common Warrants | +274,327 | 457,211 | ||
| 2026-10-20 | COLUMN GROUP III GP, LP 10% owner | Option exercise · Series E Common Warrants | +258,620 | 431,034 | ||
| 2026-10-20 | Kutzkey Tim Director | Option exercise | +485,830 | $11.60 | $5.6M | 1,386,122 |
| 2026-10-20 | Kutzkey Tim Director | Option exercise | +548,653 | $11.60 | $6.4M | 1,565,311 |
| 2026-10-20 | Kutzkey Tim Director | Option exercise | +517,241 | $11.60 | $6.0M | 862,068 |
| 2026-10-20 | Kutzkey Tim Director | Option exercise · Second Tranche Units (Right to Buy) | −728,745 | 0 | ||
| 2026-10-20 | Kutzkey Tim Director | Option exercise · Second Tranche Units (Right to Buy) | −822,980 | 0 | ||
| 2026-10-20 | Kutzkey Tim Director | Option exercise · Second Tranche Units (Right to Buy) | −775,861 | 0 | ||
| 2026-10-20 | Kutzkey Tim Director | Option exercise · Series E Common Warrants | +242,915 | 404,858 | ||
| 2026-10-20 | Kutzkey Tim Director | Option exercise · Series E Common Warrants | +274,327 | 457,211 | ||
| 2026-10-20 | Kutzkey Tim Director | Option exercise · Series E Common Warrants | +258,620 | 431,034 | ||
| 2026-07-22 | TCG Crossover GP II, LLC 10% owner | Sale | −162,500 | $21.25 | $3.5M | 574,054 |
| 2026-07-22 | TCG Crossover GP II, LLC 10% owner | Sale | −162,500 | $21.25 | $3.5M | 574,047 |
Page 1 of 12 · 237 trades